FDA Grants Breakthrough Therapy Designation to CIMZIA for Preventing Adverse Pregnancy Outcomes in Antiphospholipid Syndrome
核心洞察
The U.S. FDA granted Breakthrough Therapy Designation to CIMZIA (certolizumab pegol) for preventing placenta-mediated adverse pregnancy outcomes in pregnant women with antiphospholipid syndrome (搜索) (APS) who are lupus anticoagulant (搜索)-positive.
The designation is supported by preliminary clinical evidence from the investigator-sponsored IMPACT study, which demonstrated CIMZIA's potential to prevent adverse pregnancy outcomes in high-risk APS patients.
No FDA-approved therapies currently exist for preventing adverse pregnancy outcomes in APS, where patients are typically managed with low-dose aspirin and heparin, underscoring a substantial unmet need.
UCB (搜索) announced that the U.S. Food and Drug Administration (搜索) (FDA) has granted Breakthrough Therapy Designation (BTD) to CIMZIA (certolizumab pegol) for the prevention of placenta-mediated adverse pregnancy outcomes in pregnant women who have antiphospholipid syndrome (搜索) (APS) and are positive for lupus anticoagulant (搜索) (LA). These patients were considered at risk due to prior obstetric and blood clotting (thrombotic) events.
The designation is supported by preliminary clinical evidence from the IMPACT study and recognizes the potential of CIMZIA to address a significant unmet medical need in an area where there are currently no FDA-approved therapies for the prevention of adverse pregnancy outcomes in patients with APS.
A Significant Unmet Need in a Rare Autoimmune Disorder
APS is a rare and serious autoimmune condition that mainly affects women of childbearing age, characterized by the presence of antiphospholipid antibodies, which can cause repeated blood clots in arteries and veins. The condition is associated with serious pregnancy complications, including recurrent pregnancy loss in the first trimester, pre-eclampsia, placental insufficiency, fetal growth restriction, preterm birth, stillbirth, and a range of serious placenta-mediated adverse pregnancy outcomes.
Despite the significant burden of the condition, patients are typically managed with low-dose aspirin and heparin during pregnancy. However, no therapies are currently approved specifically for the prevention of adverse pregnancy outcomes in this patient population, highlighting a substantial unmet medical need.
"This designation is a testament to UCB (搜索)'s commitment to advancing innovation in areas of significant unmet need, including our long-standing focus on supporting women of childbearing age," said Donatello Crocetta, Chief Medical Officer and Global Head of Medical Affairs at UCB. "Building on our experience across immune-mediated conditions, we continue to explore new approaches for people living with rare diseases and other underserved conditions where treatment options remain limited."
Evidence from the IMPACT Study
IMPACT (IMProve Pregnancy in APS with Certolizumab Therapy) was an investigator-sponsored study evaluating certolizumab pegol in pregnant women with APS at high risk of adverse pregnancy outcomes. Published results demonstrated the potential of certolizumab pegol to prevent adverse pregnancy outcomes in this high-risk population.
Results from the IMPACT study demonstrated the potential of CIMZIA to prevent adverse pregnancy outcomes in women with APS considered high risk due to LA positivity and prior obstetric or thrombotic manifestations of the disease. The findings add to growing evidence implicating tumor necrosis factor (搜索) (TNF)-mediated inflammation in APS-related pregnancy complications.
"For women living with APS, pregnancy can be an especially challenging and uncertain experience," said Dr. Jane E. Salmon, Collette Kean Research Chair, Hospital for Special Surgery, and Co-Lead Investigator of the IMPACT study. "Despite current management approaches, many patients remain at risk of serious complications, including preeclampsia, intrauterine growth restriction, premature birth, and fetal death, highlighting the need for additional treatment options for this underserved population. Today's designation represents an encouraging step forward in efforts to improve outcomes for women of childbearing age and their families."
Regulatory Context
A Breakthrough Therapy Designation is granted to medicines intended to treat a serious or life-threatening condition when preliminary clinical evidence indicates the therapy may demonstrate substantial improvement over available treatments on one or more clinically significant endpoints. The designation is designed to facilitate development and expedite the FDA review of promising new therapies, providing opportunities for more intensive FDA guidance and organizational commitment to support efficient development and review. It is not a label indication approval.
The designation builds on the FDA's recent Orphan Drug Designation for CIMZIA for the prevention of placenta-mediated adverse pregnancy outcomes in pregnant patients with APS. Orphan Drug Designation is granted by the FDA to medicines intended for the treatment, prevention, or diagnosis of rare diseases or conditions affecting fewer than 200,000 people in the United States.
CIMZIA is not currently approved in pregnant women with APS, and the safety and efficacy have not been established for this use. CIMZIA is a tumor necrosis factor (搜索) (TNF) blocker with existing U.S. indications spanning Crohn's disease, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis.